Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2026-A00335-46 | Other Identifier | ANSM |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Direction Générale de l'Offre de Soins | OTHER_GOV |
| Sooma Medical | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Transcranial direct current stimulation (tDCS) is a neuromodulation method that modulates brain activity using low-intensity electrical current. Used in the treatment of depression, it is easily adaptable for both caregivers and patients, with good tolerance, under appropriate supervision.
Allowing patients to perform tDCS at home could address issues of access to care (distance from home, overall cost of care, lack of healthcare professionals, difficulty travelling for physical/psychological reasons, etc.). Studies on tDCS have highlighted the importance of regular clinical monitoring to ensure compliance and safety, which are essential factors for therapeutic efficacy.
The main objective of this study is to demonstrate the non-inferiority of tDCS performed at home versus in hospital in terms of effectiveness in reducing depressive symptoms at 6 weeks post-treatment in patients with moderate to severe depression.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| tDCS at the hospital | Active Comparator | In the control group, patients receive tDCS treatment at the hospital under nursing supervision. In the control group, patients receive tDCS treatment at the hospital under nursing supervision. |
|
| Performing tDCS at home | Experimental | As part of the home intervention group, patients undergo a self-administered tDCS treatment, but under remote nursing supervision via the SoomaDuo app (CE marked, used in accordance with the tDCS device). This device allows daily monitoring of treatment, automatic verification of stimulation parameters and complete traceability of compliance. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Distribution of study questionnaires | Other | The questionnaires will be administered to patients at DO, D10, and M2. MADRS/RSES/EQ-5D-5L/BDI/CRQ |
|
| Measure | Description | Time Frame |
|---|---|---|
| Evaluate the non-inferiority of tDCS administered at home compared to in-hospital treatment in terms of effectiveness in reducing depressive symptoms 6 weeks post-treatment, using the MADRS (Montgomery-Asberg Depression Rating Scale). | The scale ranges from 0 to 60, with 60 representing the worst possible outcome. | 2 months |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluate the response to treatment by comparing the two arms immediately post-treatment and at M2 (6 weeks post-treatment). This will be assessed by the change in the total MADRS scale score. | The scale ranges from 0 to 60, with 60 representing the worst possible outcome. | 2 Months |
| Evaluate the remission rate in each of the two arms immediately after treatment and at M2. |
Not provided
Inclusion Criteria:
Men or women over the age of 18
Psychiatric diagnosis:
Drug treatment:
o Failure of a maximum of 1 or 2 antidepressants taken successively or in combination for the current episode
Psychiatric follow-up: Receiving medical follow-up by a psychiatrist or referring physician
Ability to understand and cooperate:
Informed consent: Have given written consent to participate in the research, after receiving oral and written information about the study.
Social affiliation: Be affiliated with a social security system
Exclusion Criteria:
Psychiatric or neurological diagnoses:
History or current treatment of neuromodulation
Presence of a high risk of suicide. A risk of suicide will be considered high if the score on item 10 of the MADRS scale ("Suicidal Thoughts") is 4 or higher, and/or if there is active suicidal ideation accompanied by clinically identified intent or a plan
Addiction and substance use: Current substance use disorder other than nicotine or caffeine
Psychiatric comorbidities that may interfere with study participation, including: understanding information, adherence to the protocol, and completing CBT sessions.
Recent change in curative psychotropic treatment (antidepressant, mood stabiliser including lithium and anticonvulsants, mood-stabilising antipsychotic) in the month prior to inclusion.
Medical contraindication to stimulation:
A severe and/or progressive somatic condition requiring ongoing medical care that would interfere with participation in the study.
Limited ability to participate:
A significant cognitive impairment or sensory deficit that prevents understanding of instructions
Inability to safely perform tDCS at home, as defined by at least one of the following:
Special legal or social situation:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Damiens Choneau | Contact | 02 53 48 28 35 | +33 | bp-prom-regl@chu-nantes.fr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Clinique Mirambeau | Anglet | France |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| tDCS sessions (D1-D10) | Other | Protocol: 2 mA, 30 min, 10 working days (Monday to Friday), 2 sessions/day |
|
| Monitoring tDCS appropriation | Other | During visits to the hospital, the nurse ensures that the patient knows how to use the device correctly. |
|
| Semi-structured interviews with patients | Other | The interviews will be conducted by telephone with patients participating in the study. The purpose of these interviews is to gather information for the qualitative aspect of the implementation. |
|
| 2 months |
| Compare the change in patient self-reported depressive symptoms using the BDI-II (Beck Depression Inventory-II) in both study arms, measured immediately post-treatment and at M2 (6 weeks post-treatment). | The scale ranges from 0 to 3, where 3 representing the worst possible outcome. | 2 months |
| Assess the impact of tDCS on self-esteem using the Rosenberg Self-Esteem Scale (RSES) in both study arms, measured immediately post-treatment and at M2 (6 weeks post-treatment). | The scale ranges from 1 to 4, where 1 indicates "strongly disagree" and 4 indicates "strongly agree. | 2 months |
| Study patients' quality of life using the EQ-5D-5L after tDCS treatment in each of the two arms immediately after treatment and at M2. | The scale ranges from 0 to 100, with 0 representing the worst possible outcome. | 2 months |
| Assess the safety of the two tDCS administration modalities using the Comfort Rating Questionnaire (CRQ) in each of the two arms immediately after treatment. | The scale ranges from 0 to 10, with 10 representing the worst possible outcome. | 10 Days |
| Compare efficiency from a collective perspective and over a two-month time horizon. | Incremental cost-utility ratio (cost per QALY) at 2 months. | 2 months |
| Analyse the financial impact of the rollout of tDCS at home (budget impact analysis over 5 years) | 2 months |
| Determine the optimal implementation conditions for the effective deployment of tDCS at home across the following domain : Relevance | Qualitative analysis of data collected during semi-structured interviews with patients and their relatives regarding the suitability or unsuitability of the method of administering tDCS at home. | 2 months |
| Determine the optimal implementation conditions for the effective deployment of tDCS at home across the following domain : Acceptability |
| 2 months |
| Determine the optimal implementation conditions for the effective deployment of tDCS at home across the following domain : Fidelity | Ratio of the number of sessions completed to the number of sessions planned in each of the two groups. // Proportion of patients who discontinued the protocol before completion // Factors leading to deviations that resulted in the treatment being carried out over a longer period or in the tDCS stimulation treatment being discontinued. | 2 months |
| Determine the optimal implementation conditions for the effective deployment of tDCS at home across the following domain : Adoption | Proportion of individuals included among those identified. Description of the reasons for excluding patients who were identified but not included. Frequency of inclusions. | 2 months |
| Determine the optimal implementation conditions for the effective deployment of tDCS at home across the following domain : Implementation Costs (microcosting). | 2 months |
| Determine the optimal implementation conditions for the effective deployment of tDCS at home across the following domain : Feasibility | Number of patients who completed the full course of tDCS treatment. | 2 months |
| Determine the optimal implementation conditions for the effective deployment of tDCS at home across the following domain: Reach (Sociodemographic profile of the patients included) | 2 months |
| Determine the optimal implementation conditions for the effective deployment of tDCS at home across the following domain : Sustainability (Integration of the scheme into the facility's care programme) | 2 months |
| CH Georges Mazurelle | La Roche-sur-Yon | France |
|
| CHU de Nantes | Nantes | France |
|
| CHU de Nîmes | Nîmes | France |
|
| CH Le Rouvray | Sotteville-lès-Rouen | France |
|
| CH Léon-Jean Grégory - Thuir | Thuir | France |
|
| ID | Term |
|---|---|
| D003863 | Depression |
| ID | Term |
|---|---|
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |
Not provided
Not provided